S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
NASDAQ:VRCA

Verrica Pharmaceuticals - VRCA Stock Forecast, Price & News

$3.91
-0.13 (-3.22%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.88
$4.13
50-Day Range
$1.92
$4.04
52-Week Range
$1.77
$14.79
Volume
108,985 shs
Average Volume
277,186 shs
Market Capitalization
$107.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.80

Verrica Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
273.4% Upside
$14.60 Price Target
Short Interest
Bearish
6.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.39mentions of Verrica Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$3.59 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.13) to ($1.20) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

355th out of 1,125 stocks

Pharmaceutical Preparations Industry

175th out of 554 stocks

VRCA stock logo

About Verrica Pharmaceuticals (NASDAQ:VRCA) Stock

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on VRCA shares. Royal Bank of Canada cut Verrica Pharmaceuticals from an "outperform" rating to a "sector perform" rating and reduced their price target for the stock from $16.00 to $4.00 in a report on Wednesday, May 25th. Needham & Company LLC cut Verrica Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Wednesday, May 25th. Finally, HC Wainwright reiterated a "buy" rating and issued a $12.00 price objective on shares of Verrica Pharmaceuticals in a report on Wednesday, June 29th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $14.80.

Verrica Pharmaceuticals Stock Up 1.7 %

Verrica Pharmaceuticals stock traded up $0.07 during mid-day trading on Monday, reaching $4.11. 553 shares of the stock traded hands, compared to its average volume of 276,484. The business's 50-day moving average is $2.80 and its 200-day moving average is $5.61. Verrica Pharmaceuticals has a 12-month low of $1.77 and a 12-month high of $14.79.

Insider Buying and Selling at Verrica Pharmaceuticals

In related news, major shareholder Perceptive Advisors Llc purchased 1,428,571 shares of the company's stock in a transaction on Tuesday, July 5th. The shares were bought at an average cost of $2.10 per share, for a total transaction of $2,999,999.10. Following the transaction, the insider now owns 5,038,983 shares of the company's stock, valued at $10,581,864.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director John A. Stalfort III bought 238,095 shares of the firm's stock in a transaction on Tuesday, July 5th. The stock was acquired at an average cost of $2.10 per share, with a total value of $499,999.50. Following the transaction, the director now directly owns 700,205 shares in the company, valued at approximately $1,470,430.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Perceptive Advisors Llc purchased 1,428,571 shares of the firm's stock in a transaction on Tuesday, July 5th. The shares were purchased at an average price of $2.10 per share, for a total transaction of $2,999,999.10. Following the completion of the purchase, the insider now directly owns 5,038,983 shares of the company's stock, valued at $10,581,864.30. The disclosure for this purchase can be found here. Insiders purchased 1,703,689 shares of company stock worth $3,587,497 over the last 90 days. Corporate insiders own 43.50% of the company's stock.

Receive VRCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRCA Stock News Headlines

Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up
See More Headlines
Receive VRCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRCA Company Calendar

Last Earnings
11/12/2021
Today
8/16/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRCA
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.60
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+278.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-35,080,000.00
Pretax Margin
-6,357.67%

Debt

Sales & Book Value

Annual Sales
$12 million
Book Value
$1.18 per share

Miscellaneous

Free Float
15,548,000
Market Cap
$107.60 million
Optionable
Not Optionable
Beta
2.16














VRCA Stock - Frequently Asked Questions

Should I buy or sell Verrica Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VRCA shares.
View VRCA analyst ratings
or view top-rated stocks.

What is Verrica Pharmaceuticals' stock price forecast for 2022?

6 brokerages have issued twelve-month price objectives for Verrica Pharmaceuticals' stock. Their VRCA share price forecasts range from $4.00 to $20.00. On average, they anticipate the company's stock price to reach $14.80 in the next year. This suggests a possible upside of 278.5% from the stock's current price.
View analysts price targets for VRCA
or view top-rated stocks among Wall Street analysts.

How have VRCA shares performed in 2022?

Verrica Pharmaceuticals' stock was trading at $9.16 at the start of the year. Since then, VRCA shares have decreased by 57.3% and is now trading at $3.91.
View the best growth stocks for 2022 here
.

When is Verrica Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our VRCA earnings forecast
.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.04.

What other stocks do shareholders of Verrica Pharmaceuticals own?
When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Who are Verrica Pharmaceuticals' major shareholders?

Verrica Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (5.81%), Millennium Management LLC (0.49%), Kornitzer Capital Management Inc. KS (0.47%), Miracle Mile Advisors LLC (0.45%), Renaissance Technologies LLC (0.17%) and Northern Trust Corp (0.15%). Insiders that own company stock include A Brian Davis, Christopher G Hayes, Craig Ballaron, John A Stalfort III, Matt Davidson, Paul B Manning, Paul B Manning, Perceptive Advisors Llc and Ted White.
View institutional ownership trends
.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $3.91.

How much money does Verrica Pharmaceuticals make?

Verrica Pharmaceuticals (NASDAQ:VRCA) has a market capitalization of $107.60 million and generates $12 million in revenue each year. The company earns $-35,080,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The official website for the company is www.verrica.com. The company can be reached via phone at (434) 453-3300 or via email at info@verrica.com.

This page (NASDAQ:VRCA) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.